Abstract:Hedgehog (Hh) pathway is involved in epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) maintenance resulting in tumor progression. GDC-0449, an inhibitor of Hh pathway component smoothened (Smo) has shown promise in the treatment of various cancers including pancreatic cancer. However, the emergence of resistance during GDC-0449 treatment with numerous side effects limits its use. Therefore, here we report the design, synthesis and evaluation of novel GDC-0449 analogs using N-[3-(2-pyridinyl) phenyl] benzamide scaffold. Cell-based screening followed by molecular simulation revealed 2-chloro-N 1-[4-chloro-3-(2-pyridinyl)phenyl]-N 4,N 4-bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide (MDB5) as most potent analog, binding with an extra interactions in seven-transmembrane (7-TM) domain of Smo due to an additional 2-pyridylmethyl group than GDC-0449. Moreover, MDB5 was more efficient in inhibiting Hh pathway components as measured by Gli-1 and Shh at transcriptional and translational levels. Additionally, a significant reduction of ALDH1, CD44 and Oct-3/4, key markers of pancreatic CSC was observed when MIA PaCa-2 cells were treated with MDB5 compared to GDC-0449. In a pancreatic tumor mouse model, MDB5 containing nanoparticles treated group showed significant inhibition of tumor growth without loss in body weight. These evidence highlight the enhanced Hh pathway inhibition and anticancer properties of MDB5 leaving a platform for mono and/or combination therapy.

Design, Synthesis, and Biological Study of 6,7-Dihydro-5 H -Pyrano[2,3-d]pyrimidine Derivatives As Novel Hedgehog Signaling Pathway Inhibitors

Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.

The Discovery of Novel N-(2-pyrimidinylamino) Benzamide Derivatives As Potent Hedgehog Signaling Pathway Inhibitors

4-(Pyrimidin-2-ylamino)benzamide Derivatives:Design, Synthesis, and Hedgehog Signaling Pathway Inhibition Study

Discovery of Novel 4-(2-pyrimidinylamino)benzamide Derivatives As Highly Potent and Orally Available Hedgehog Signaling Pathway Inhibitors

Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.

Synthesis and Pharmacological Evaluation of Trifluoromethyl Containing 4-(2-pyrimidinylamino)benzamides As Hedgehog Signaling Pathway Inhibitors

Five-membered Heteroaromatic Ring Fused-Pyrimidine Derivatives: Design, Synthesis, and Hedgehog Signaling Pathway Inhibition Study.

Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.

Synthesis and Evaluation of Novel Benzylphthalazine Derivatives As Hedgehog Signaling Pathway Inhibitors.

Design, Synthesis, and Biological Evaluation of Optimized Phthalazine Derivatives As Hedgehog Signaling Pathway Inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Synthesis and Biological Evaluation of Novel Benzamide Derivatives As Potent Smoothened Antagonists.

A highly enantioselective intramolecular 1,3-dipolar cycloaddition yields novel pseudo-natural product inhibitors of the Hedgehog signaling pathway

Discovery of Novel Macrocyclic Hedgehog Pathway Inhibitors Acting by Suppressing the Gli-Mediated Transcription.

Introduction of fluorine to phenyl group of 4-(2-pyrimidinylamino)benzamides leading to a series of potent hedgehog signaling pathway inhibitors

Design, Synthesis, and Evaluation of Inhibitors of Hedgehog Acyltransferase

Design, Synthesis, and Structure–activity-Relationship of Tetrahydrothiazolopyridine Derivatives As Potent Smoothened Antagonists

Discovery of a 6-(Pyridin-3-yl)benzo[d]thiazole Template for Optimization of Hedgehog and PI3K/AKT/mTOR Dual Inhibitors.

Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer

Discovery of Small Molecule Inhibitors Targeting the Sonic Hedgehog